Medicines/Item |
Section |
Status |
Link Name / Link URL |
Nintedanib |
08.01 |
Formulary
|
NICE TA347 : Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer |
Nintedanib |
08.01 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Abatacept |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Abciximab |
02.09 |
Restricted Use
|
NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Abiraterone Acetate |
08.03.04.02 |
Formulary
|
NICE TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen |
Abiraterone Acetate |
08.03.04.02 |
Formulary
|
NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Aclidinium Bomide |
03.01.02 |
Formulary
|
NICE ESNM8: Chronic obstructive pulmonary disease: aclidinium bromide |
Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Adalimumab |
13.05.03 |
Restricted Use
|
TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA146: Psoriasis - adalimumab |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment of arthritis after failure of a TNF inhibitor |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib |
Aflibercept |
08.01 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA294: Macular degeneration (wet age-related) - aflibercept |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409 : Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
Alendronic Acid Effervescent tablets |
06.06.02 |
Formulary
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
Alirocumab |
02.12 |
Formulary
|
TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alitretinoin |
13.05.01 |
Restricted Use
|
NICE TA177: Eczema (chronic) - alitretinoin |
Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264 - Alteplase for treating acute ischaemic stroke |
Alteplase |
02.10.02 |
Non Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
Apremilast |
10.01.03 |
Restricted Use
|
NICE TA 433: Apremilast for treating active psoriatic arthritis |
Apremilast |
13.05.02 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
Asfotase alfa |
09.08.01 |
Restricted Use
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
Atezolizumab |
08.02.03 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
Atorvastatin |
02.12 |
Formulary
|
NICE CG181 - Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Avelumab |
08.02.03 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
Avelumab |
08.02.03 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
Axicabtagene ciloleucel |
08.02.04 |
Formulary
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
Azacitidine |
08.01.03 |
Formulary
|
TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
Azacitidine |
08.03.01 |
Formulary
|
TA 399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
Azathioprine |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
Beclometasone and formoterol |
03.02 |
Formulary
|
NICE ESNM53 Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) |
Belimumab |
10.01.03 |
Restricted Use
|
NICE TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Breast cancer with capecitabine |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Bevacizmab in combination with taxane |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA212: Colorectal cancer (metastatic) - bevacizumab |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
Blinatumomab |
08.02.03 |
Formulary
|
NICE TA589:Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
Blinatumomab |
08.02.03 |
Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
Boceprevir |
05.03.03 |
Restricted Use
|
NICE TA253: Hepatitis C (genotype 1) - boceprevir |
Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA311: Multiple myeloma - bortezomib (induction therapy |
Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA299: Leukaemia (chronic myeloid) - bosutinib |
Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA129: Multiple myeloma - bortezomib |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
Botulinum neurotoxin Type A |
04.12 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
Brodalumab |
10.01.03 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391 - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
Cangrelor |
02.09 |
Formulary
|
NICE TA351 : Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminatedappraisal) |
Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Capecitabine for the treatment of advanced gastric cancer |
Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
Carmustine |
08.01.01 |
Formulary
|
NICE TA121:Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Cemiplimab |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, eternecept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA176: Colorectal cancer (first line) - cetuximab |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA145: Head and neck cancer - cetuximab |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Ciclosporin |
11.08.01 |
Formulary
|
TA369 : Ciclosporin for treating dry eye disease that has not improved despitetreatment with artificial tears |
Ciclosporin |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
Ciclosporin |
01.05.03 |
Formulary
|
NICE NG130: Ulcerative colitis: management |
Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
Colistimethate inhaler |
05.01.07 |
Restricted Use
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA406 : Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-nonsmall- |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Cytarabine-Daunorubicin liposomal |
08.01.03 |
Formulary
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
Daclizumab |
08.02.02 |
Formulary
|
NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis |
Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Dapagliflozin |
06.01.02.03 |
Formulary
|
TA597: Dapagliflozin with insulin for treating type 1 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 : Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 288: Dapagliflozin in combination therapy for treating type 2 diabetes |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
Denosumab |
06.06.02 |
Restricted Use
|
TA265 : Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA349 : Dexamethasone intravitreal implant for treating diabetic macular oedema |
Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
Dimethyl fumerate |
13.05.03 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
Dinutuximab |
08.02.03 |
Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
Doxorubicin hydrochloride |
08.01.02 |
Non Formulary
|
NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) |
Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
Elbasvir-grazoprevir |
05.03.03.02 |
Restricted Use
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura |
Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies fortreating type 2 diabetes |
Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
Entecavir |
05.03.03 |
Restricted Use
|
NICE TA153: Hepatitis B (chronic) - etecavir |
Entecavir |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (incorporates TA153) |
Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Eplerenone |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
Eribulin |
08.01.05 |
Formulary
|
NICE TA423- Eribulin for treating advanced or metastatic cancer after 2 or more chemotherapies |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) |
Erlotinib |
08.01.05 |
Formulary
|
TA374 Erlotinib and Gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Erlotinib |
08.01.05 |
Formulary
|
TA258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
Erlotinib |
08.01.05 |
Formulary
|
TA227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. |
Etanercept |
13.05.03 |
Restricted Use
|
NICE TA103: Psoriasis - efalizumab and etanercept |
Etelcalcetide |
09.05.01.02 |
Restricted Use
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
Everolimus |
08.01.05 |
Formulary
|
NICE T432: Everolimus for advanced renal cell carcinoma after previous treatment |
Everolimus |
08.01.05 |
Formulary
|
NICE TA421:Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
Everolimus |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Everolimus |
08.01.05 |
Non Formulary
|
NICE TA348 : Everolimus for preventing organ rejection in liver transplantation |
Evolocumab |
02.12 |
Formulary
|
TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Exemestane |
08.03.04.01 |
Formulary
|
TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous - familial and non-familial hypercholesterolaemia |
Febuxostat |
10.01.04 |
Formulary
|
TA164 Febuxostat for the management of Hyperuricaemia in People with Gout |
Finasteride |
06.04.02 |
Formulary
|
NICE CG 97 Lower urinary tract symptoms in men;management |
Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590 : Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
Formoterol/Beclometasone |
03.02 |
Formulary
|
NICE ESNM22 Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment |
Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer - not recommended |
Galantamine M/R capsules |
04.11 |
Formulary
|
Information from NICE |
Gaviscon®Advance |
01.01.02 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
Gemcitabine |
08.01.03 |
Formulary
|
NICE NG85: Pancreatic cancer in adults: diagnosis and management |
Gemtuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
Glecaprevir - pibrentasvir |
05.03.03.02 |
Restricted Use
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Glycopyrronium Bromide |
03.01.02 |
Formulary
|
NICE ESNM9: Chronic obstructive pulmonary disease: Glycopyrronium Bromide |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
Golimumab |
01.05.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
Idelalisib |
08.01.05 |
Formulary
|
NICE TA359 -Idelalisib for treating chronic lymphocytic leukaemia |
Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
Imatinib |
08.01.05 |
Formulary
|
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia |
Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Infliximab |
13.05.03 |
Non Formulary
|
NICE TA134: Infliximab for psoriasis |
Infliximab |
13.05.03 |
Restricted Use
|
TA134 - Infliximab for the treatment of adults with psoriasis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
Infliximab |
01.05.03 |
Formulary
|
NICE TA163 - Infliximab for acute exacerbations of ulcerative colitis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
Inotuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of chronic hepatitis C |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
CG131 - Colorectal cancer: The diagnosis and management of colorectal cancer |
Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina: management |
Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Larotrectinib |
08.02.04 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
Ledipasvir - Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA363 - Ledipasvir-sofosbuvir for treating Chronic Hepatitis C |
Leflunomide |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma |
Lenalidomide plus Dexamethasone |
08.02.04 |
Formulary
|
NICE TA 586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib |
Lenalidomide plus Dexamethasone |
08.02.04 |
Formulary
|
NICE TA 587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma |
Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults:management |
Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318 :Lubiprostone for treating chronic idiopathic constipation |
Lumacaftor-ivacaftor |
08.01.02 |
Non Formulary
|
TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Mannitol Dry Powder |
03.07 |
Formulary
|
TA266 - Mannitol dry powder for inhalation for treating cystic fibrosis |
Mannitol inhalation |
20 |
Non Formulary
|
NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
Methotrexate |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
Methylprednisolone |
06.03.02 |
Non Formulary
|
NICE CG8: Multiple Sclerosis; management in primary and secondary care. |
Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid |
Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide |
Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
Naldemedine |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for treating opioid-induced constipation |
Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid-induced constipation |
Naltrexone |
04.10.03 |
Restricted Use
|
NICE TA115: Drug misuse - naltrexone |
Naltrexone-bupropion |
04.05.02 |
Non Formulary
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity |
Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
Neratinib |
08.03.04.01 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
Niraparib |
08.01.05 |
Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
Nivolumab |
08.02.04 |
Restricted Use
|
TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.04 |
Restricted Use
|
TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
Nivolumab |
08.02.03 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
Nusinersen® |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
Ocriplasmin |
11.08.02 |
Restricted Use
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
Ofatumumab |
08.02.03 |
Formulary
|
NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344 : Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Olaparib |
08.01.05 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Olaratumab |
08.01.05 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278 - Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) |
Omalizumab |
03.04.02 |
Non Formulary
|
NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) |
Ombitasvir with Paritaprevir and Ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Osimertinib |
08.01.05 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Osimertinib |
08.01.05 |
Formulary
|
NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
Osimertinib |
08.01.05 |
Formulary
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
Oxaliplatin |
08.01.05 |
Restricted Use
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
Palbociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Palbociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Panitumumab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
Parenteral Nutrition |
09.03 |
Non Formulary
|
CG32: Oral nutrition support, enteral tube feeding and Parenteral Nutrition |
Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: guidance on pegaptanib in AMD (August 2008) |
PEGASPARGASE |
20 |
Non Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Peginterferon Beta-1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
Pemetrexed |
08.01.03 |
Formulary
|
TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190:Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer |
Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
Peptac®Liquid |
01.01.02 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
Pharmalgen |
03.04.02 |
Restricted Use
|
TA246 - Pharmalgen for the treatment of bee and wasp venom allergy |
Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Pirfenidone |
03.11 |
Restricted Use
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
pirfenidone |
20 |
Non Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone |
Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
Polatuzumab vedotin |
08.02.03 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
Ponatinib |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
Prasugrel |
02.09 |
Formulary
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
Raloxifene Hydrochloride |
06.04.01.01 |
Non Formulary
|
NICE TA160: quick reference guide on osteoporosis |
Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab |
Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance |
Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA274: Macular oedema (diabetic) - ranibizumab |
Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina: management |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Ribociclib |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Rifaximin |
05.01.07 |
Formulary
|
NICE TA337 : Rifaximin for preventing episodes of overt hepatic encephalopathy |
Riluzole |
04.09.03 |
Formulary
|
NICE TA 20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease |
Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
Risedronate |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA65: Non-Hodgkin’s lymphoma - rituximab |
Rituximab iv |
08.02.03 |
Formulary
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 : Rivaroxaban for preventing adverse outcomes after Acute management of Acute coronary syndrome |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
Roflumilast |
03.03.03 |
Restricted Use
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
Rucaparib |
08.02.04 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
Sacubitril valsartan |
02.05.05 |
Formulary
|
NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
Sarilumab |
08.02.04 |
Restricted Use
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA350 : Secukinumab for treating moderate to severe plaque psoriasis |
Semaglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults:management |
Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA361 - Simprevir in combination with sofosbuvir for treating genotype 1 or 4 Chronic Hepatitis C |
Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
Sofosbuvir-velpatasvir-voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
Sofosubvir-velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
Sulfasalazine enteric coated |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
Sunitinib |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482:Immunosuppressive therapy for kidney transplants in children and young people |
Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481:Immunosuppressive therapy for kidney transplant in adults |
Tacrolimus Ointment 0.03% and 0.10% |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
Telaprevir |
05.03.03 |
Restricted Use
|
NICE TA252: Hepatitis C (genotype 1) - telaprevir |
Telbivudine |
05.03.03.01 |
Restricted Use
|
NICE TA154: Hepatitis B - telbivudine |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Temsirolimus |
08.01.05 |
Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
Temsirolimus |
08.01.05 |
Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173 |
Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
Ticagrelor |
02.09 |
Formulary
|
NICE TA420:Ticagrelor for preventing atherothrombotic ardial infarction |
Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA554: Tisagenlecleucel for treating relapsed orrefractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
Tobramycin inhaler |
05.01.04 |
Restricted Use
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Tofacitinib |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
Tolvaptan |
06.05.02 |
Restricted Use
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
Topotecan |
08.01.05 |
Formulary
|
TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
Trametinib |
08.01.05 |
Formulary
|
NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
Trastuzumab |
08.01.05 |
Formulary
|
NICE NG101 Early and locally advanced breast cancer diagnosis and managment |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Trifluridine tipiracil |
08.01.03 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
Umeclidinium Bromide |
03.01.02 |
Formulary
|
NICE ESNM52: Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) |
Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
Ustekinumab |
13.05.03 |
Formulary
|
TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
Vemurafenib |
08.01.05 |
Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Vilanterol/Fluticasone furoate |
03.02 |
Formulary
|
NICE ESM34 Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler |
Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
Vinorelbine |
08.01.04 |
Formulary
|
NICE CG81 : Advanced breast cancer: Diagnosis and treatment |
Vismodegib |
08.01.05 |
Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
Vortioxetine |
04.03.03 |
Formulary
|
TA367 - Vortioxetine for treating major depressive episodes |
Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia |